Net Cash Provided by (Used in) Financing Activities of KalVista Pharmaceuticals, Inc. from 30 Apr 2016 to 31 Jul 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
KalVista Pharmaceuticals, Inc. quarterly and annual Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 30 Apr 2016 to 31 Jul 2025.
  • KalVista Pharmaceuticals, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Jul 2025 was $23,210,000, a 674% increase year-over-year.
  • KalVista Pharmaceuticals, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $159,727,000, a 6% increase from 2023.
  • KalVista Pharmaceuticals, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $150,714,000, a 159% increase from 2022.
  • KalVista Pharmaceuticals, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $58,116,000, a 3576% increase from 2021.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

KalVista Pharmaceuticals, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $23,210,000 +$20,210,000 +674% 01 May 2025 31 Jul 2025 10-Q 11 Sep 2025 2026 Q1
Q2 2024 $3,000,000 +$2,796,000 +1371% 01 May 2024 31 Jul 2024 10-Q 11 Sep 2025 2026 Q1
Q2 2023 $204,000 +$36,000 +21% 01 May 2023 31 Jul 2023 10-Q 05 Sep 2024 2025 Q1
Q2 2022 $168,000 -$440,000 -72% 01 May 2022 31 Jul 2022 10-Q 07 Sep 2023 2024 Q1
Q2 2021 $608,000 +$562,000 +1222% 01 May 2021 31 Jul 2021 10-Q 08 Sep 2022 2023 Q1
Q2 2020 $46,000 -$11,354,000 -100% 01 May 2020 31 Jul 2020 10-Q 09 Sep 2021 2022 Q1
Q2 2019 $11,400,000 +$6,452,000 +130% 01 May 2019 31 Jul 2019 10-Q 14 Sep 2020 2021 Q1
Q2 2018 $4,948,000 01 May 2018 31 Jul 2018 10-Q 09 Sep 2019 2020 Q1

KalVista Pharmaceuticals, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $159,727,000 +$9,013,000 +6% 01 May 2024 30 Apr 2025 10-K 10 Jul 2025 2025 FY
2023 $150,714,000 +$92,598,000 +159% 01 May 2023 30 Apr 2024 10-K 10 Jul 2025 2025 FY
2022 $58,116,000 +$56,535,000 +3576% 01 May 2022 30 Apr 2023 10-K 11 Jul 2024 2024 FY
2021 $1,581,000 -$210,536,000 -99% 01 May 2021 30 Apr 2022 10-K 11 Jul 2024 2024 FY
2020 $212,117,000 +$200,533,000 +1731% 01 May 2020 30 Apr 2021 10-K 10 Jul 2023 2023 FY
2019 $11,584,000 -$76,359,000 -87% 01 May 2019 30 Apr 2020 10-K 07 Jul 2022 2022 FY
2018 $87,943,000 +$78,957,000 +879% 01 May 2018 30 Apr 2019 10-K 13 Jul 2021 2021 FY
2017 $8,986,000 +$8,984,000 01 May 2017 30 Apr 2018 10-K 01 Jul 2020 2020 FY
2016 $2,000* -$33,001,000 01 May 2016 30 Apr 2017 10-K 16 Jul 2019 2019 FY
2015 $33,003,000 01 May 2015 30 Apr 2016 10-K 30 Jul 2018 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.